Arne Reimers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Arne Reimers has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
Eylert Brodtkorb
Department of neurology and clinical neurophysiology, St. Olavs University Hospital, Trondheim, Norway
16 shared publicationsGrethe Helde
Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology (NTNU), Trondheim, Norway
10 shared publications- Geir Bråthen
Department of Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway
5 shared publications - Hanna Ljung
Division of Neurology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
4 shared publications Olav Spigset
Department of Clinical Pharmacology, St. Olavs University Hospital, Trondheim, Norway
4 shared publications- Olav Spigset
Department of Clinical Pharmacology, St. Olav University Hospital, Trondheim, Norway
4 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 185
Cognitive Outcomes During Adjunctive Cenobamate Treatment in Patients with Drug-Resistant Epilepsy: An Interim Analysis of a Prospective Observational Study
- 1 October 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 185
Open AccessCognitive Outcomes During Adjunctive Cenobamate Treatment in Patients with Drug-Resistant Epilepsy: An Interim Analysis of a Prospective Observational Study
- Open Access
- 7 June 2025
- Published by Springer Nature in Drug Safety
- Vol. 48 (7) , 841
Authors’ reply to Chaker Ben Salem’s comment on: “Drug-Induced Cognitive Impairment”
- 7 June 2025
- Published by Springer Nature in Drug Safety
- Vol. 48 (7) , 841
Open AccessAuthors’ reply to Chaker Ben Salem’s comment on: “Drug-Induced Cognitive Impairment”
- Open Access
- 24 December 2024
- Published by Springer Nature in Drug Safety
- Vol. 48 (4) , 339-361
Drug-Induced Cognitive Impairment
Drug-induced cognitive impairment (DICI) is a well-established, yet under-recognised, complication of many types of pharmacological treatment. While there is a large body of scientific literature on DICI, most papers are about drug-induced dementia in the elderly and one specific drug class. However, DICI also comprises subclinical symptoms, domain-specific forms of cognitive impairment as well as mild cognitive impairment (MCI), and delirium. Even mild forms of DICI, if not recognised as such, can have deleterious and life-long consequences. In addition, DICI also occurs in younger adults and in children, and has been reported with many different drug classes. The aim of this review is to raise awareness of DICI by providing an overview on the type(s) and symptoms of observed DICI and the suspected underlying mechanism(s) for various drug classes: antiseizure medications, antidepressants, antiparkinsonian drugs, antipsychotics, lithium, benzodiazepines/Z-drugs, opioids, first-generation antihistamines, drugs for urinary incontinence, proton pump inhibitors, glucocorticoids, NSAIDs, statins, antihypertensives, and chemotherapeutic agents.
- 24 December 2024
- Published by Springer Nature in Drug Safety
- Vol. 48 (4) , 339-361
Open AccessDrug-Induced Cognitive Impairment
Drug-induced cognitive impairment (DICI) is a well-established, yet under-recognised, complication of many types of pharmacological treatment. While there is a large body of scientific literature on DICI, most papers are about drug-induced dementia in the elderly and one specific drug class. However, DICI also comprises subclinical symptoms, domain-specific forms of cognitive impairment as well as mild cognitive impairment (MCI), and delirium. Even mild forms of DICI, if not recognised as such, can have deleterious and life-long consequences. In addition, DICI also occurs in younger adults and in children, and has been reported with many different drug classes. The aim of this review is to raise awareness of DICI by providing an overview on the type(s) and symptoms of observed DICI and the suspected underlying mechanism(s) for various drug classes: antiseizure medications, antidepressants, antiparkinsonian drugs, antipsychotics, lithium, benzodiazepines/Z-drugs, opioids, first-generation antihistamines, drugs for urinary incontinence, proton pump inhibitors, glucocorticoids, NSAIDs, statins, antihypertensives, and chemotherapeutic agents.
- 12 August 2024
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 25 (12) , 1575-1577
Pharmacotherapy for focal epilepsy: how close are we to a cure?
- 12 August 2024
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 25 (12) , 1575-1577
Pharmacotherapy for focal epilepsy: how close are we to a cure?
- Open Access
- 16 November 2023
- Published by Springer Nature in Drug Safety
- Vol. 47 (1) , 23-28
Cognitive Safety is Largely Ignored in Clinical Drug Trials: A Study of Registered Study Protocols
Background and Objective The number of reports on suspected drug-induced memory impairment submitted to the US Food and Drug Administration increased 30-fold from 2000 to 2022. Drugs are the most common cause of reversible dementia. However, there is very little research on drug-induced cognitive impairment. The aim of this study was to investigate if and how an assessment of cognitive safety was included in recent, registered, controlled, clinical drug trials. Methods The clinical trials registry (www.clinicaltrials.gov) was searched for randomized controlled clinical trials with available study protocols. After excluding irrelevant trials such as surgical procedures, local or short-term treatment, and dietary supplements, 803 trials were included in this study. The protocols were manually reviewed for information on if, and how, cognitive safety had been assessed. Trial drugs were categorized into those targeting the central nervous system or not, as well as older and newer drugs. Methods used for the assessment of cognitive function were categorized into questionnaires, screening instruments, and neuropsychological tests. If the trial results were published, we examined whether the publication contained any data on cognitive safety that had emerged from the trial. Results The start dates of the screened trials ranged from 31 July, 2009, to 4 April, 2021. Out of the 803 trials, 52 (6.5%) actively assessed cognitive safety. The remaining trials relied solely on spontaneous reporting. Of 429 trials studying a new drug, 32 (7.5%) actively assessed cognitive safety. One hundred and fifty-eight trials examined drugs intended to, or known to have, pharmacological effects on the central nervous system. Of these, 21 (13.5%) assessed cognitive safety. Most of the trials that assessed cognitive safety used either crude screening tools or questionnaires. Conclusions Cognitive safety is largely ignored by recent controlled clinical trials. This applies even to trials assessing new drugs and trials assessing central nervous system drugs. There is an urgent need for drug manufacturers, regulatory authorities, and the medical profession to address the cognitive safety of drugs.
- 16 November 2023
- Published by Springer Nature in Drug Safety
- Vol. 47 (1) , 23-28
Open AccessCognitive Safety is Largely Ignored in Clinical Drug Trials: A Study of Registered Study Protocols
Background and Objective The number of reports on suspected drug-induced memory impairment submitted to the US Food and Drug Administration increased 30-fold from 2000 to 2022. Drugs are the most common cause of reversible dementia. However, there is very little research on drug-induced cognitive impairment. The aim of this study was to investigate if and how an assessment of cognitive safety was included in recent, registered, controlled, clinical drug trials. Methods The clinical trials registry (www.clinicaltrials.gov) was searched for randomized controlled clinical trials with available study protocols. After excluding irrelevant trials such as surgical procedures, local or short-term treatment, and dietary supplements, 803 trials were included in this study. The protocols were manually reviewed for information on if, and how, cognitive safety had been assessed. Trial drugs were categorized into those targeting the central nervous system or not, as well as older and newer drugs. Methods used for the assessment of cognitive function were categorized into questionnaires, screening instruments, and neuropsychological tests. If the trial results were published, we examined whether the publication contained any data on cognitive safety that had emerged from the trial. Results The start dates of the screened trials ranged from 31 July, 2009, to 4 April, 2021. Out of the 803 trials, 52 (6.5%) actively assessed cognitive safety. The remaining trials relied solely on spontaneous reporting. Of 429 trials studying a new drug, 32 (7.5%) actively assessed cognitive safety. One hundred and fifty-eight trials examined drugs intended to, or known to have, pharmacological effects on the central nervous system. Of these, 21 (13.5%) assessed cognitive safety. Most of the trials that assessed cognitive safety used either crude screening tools or questionnaires. Conclusions Cognitive safety is largely ignored by recent controlled clinical trials. This applies even to trials assessing new drugs and trials assessing central nervous system drugs. There is an urgent need for drug manufacturers, regulatory authorities, and the medical profession to address the cognitive safety of drugs.
- 1 January 2021
- Published by Springer Nature
- p. 140-158
Antiepileptic Drugs
- Open Access
- 1 January 2021
- Published by Elsevier in Epilepsy & Behavior
- Vol. 114, 107554
Widespread skeptic attitudes among people with epilepsy toward generic antiseizure drugs – A Swedish survey study
- 1 January 2021
- Published by Elsevier in Epilepsy & Behavior
- Vol. 114, 107554
Open AccessWidespread skeptic attitudes among people with epilepsy toward generic antiseizure drugs – A Swedish survey study
- 21 May 2020
- Published by Springer Nature
- p. 1-19
Antiepileptic Drugs
- 28 March 2019
- Published by Wiley in Bipolar Disorders
- Vol. 21 (4) , 372-373
Lamotrigine, bipolar disorder, and the pill‐free week
- 28 March 2019
- Published by Wiley in Bipolar Disorders
- Vol. 21 (4) , 372-373
Lamotrigine, bipolar disorder, and the pill‐free week
- Open Access
- 25 March 2019
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 20 (8) , 909-915
An evaluation of zonisamide, including its long-term efficacy, for the treatment of focal epilepsy
Introduction: About 70 million people worldwide are estimated to suffer from epilepsy. Despite a large variety of old and new antiepileptic drugs on the market, about 30% of people with epilepsy do not become seizure-free with medical treatment. This is a major individual and public health burden. Most of these difficult-to-treat patients are having focal seizures. Zonisamide is effective against focal seizures in adults and children and, thus, a therapeutic option for such patients. Its safety profile needs special attention. Areas covered: Herein, the authors discuss the pharmacology, clinical efficacy and the adverse effects of zonisamide. The article is derived from clinical trial data, long-term studies, meta-analyses, review articles, text books, webpages, and official license information. Expert opinion: Zonisamide has proven to be efficacious in focal epilepsy in children and adults, although it is not more effective than carbamazepine or other antiepileptic drugs. It is also effective in generalized epilepsy and in several other conditions of the CNS. Its safety profile may prevent it from becoming a first-line drug for focal epilepsy or any other indication.
- 25 March 2019
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 20 (8) , 909-915
Open AccessAn evaluation of zonisamide, including its long-term efficacy, for the treatment of focal epilepsy
Introduction: About 70 million people worldwide are estimated to suffer from epilepsy. Despite a large variety of old and new antiepileptic drugs on the market, about 30% of people with epilepsy do not become seizure-free with medical treatment. This is a major individual and public health burden. Most of these difficult-to-treat patients are having focal seizures. Zonisamide is effective against focal seizures in adults and children and, thus, a therapeutic option for such patients. Its safety profile needs special attention. Areas covered: Herein, the authors discuss the pharmacology, clinical efficacy and the adverse effects of zonisamide. The article is derived from clinical trial data, long-term studies, meta-analyses, review articles, text books, webpages, and official license information. Expert opinion: Zonisamide has proven to be efficacious in focal epilepsy in children and adults, although it is not more effective than carbamazepine or other antiepileptic drugs. It is also effective in generalized epilepsy and in several other conditions of the CNS. Its safety profile may prevent it from becoming a first-line drug for focal epilepsy or any other indication.